Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for ...
Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...
Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer ...
Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s ...
The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year ...
Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...
Ozempic and its contemporaries are the new craze. But would you believe it when we say that these weight-loss drugs would be ...
Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...
Drug compounders have filed a lawsuit against the FDA for removing Novo Nordisk's Wegovy and Ozempic from its shortage list. This decision restricts compounders from selling cheaper versions, despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results